Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Biogen Inc

3 Biotech Stocks Set to Revolutionize Medicine

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To capitalize on the industry’s expansion, it could be wise to invest in fundamentally sound biotech stocks, Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which have the potential to revolutionize medicine. Read…

StockNews.com

3 Biotech Stocks With Huge Upside Based on Analyst Price Targets

The biotech sector’s long-term growth is fueled by strong government support, increasing funding and M&A activities, and rapid AI adoption. Therefore, quality biotech stocks Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), and Biogen (BIIB) with major upside could be ideal additions to your portfolio. Keep reading.

StockNews.com

3 Biotech Stocks Wall Street Predicts Will Skyrocket

Biotech companies could gain the financial flexibility to accelerate their innovations with the Fed’s recent rate cut. To capitalize on this opportunity, consider investing in fundamentally sound biotech stocks Biogen (BIIB), Royalty Pharma (RPRX), and BioMarin Pharmaceutical (BMRN), that are poised to skyrocket. Learn more.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Biotech Stocks That Could Deliver Big Gains

The biotech industry is poised for significant growth, fueled by advanced technologies, the increased commercialization of new therapeutics, and increased R&D spending on treatments for new and rare diseases. Hence, investors should consider strong biotech stocks such as Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which could deliver big…

StockNews.com

3 Healthcare Stocks With High Analyst Price Targets

Recent innovations, successful trials, and increased research and development spending in the healthcare sector further boost the sector’s appeal today. Given this momentum, investors might consider investing in stocks with high analyst price targets, such as Pfizer (PFE), Biogen (BIIB), and BioMarin Pharmaceutical (BMRN). Read on….

StockNews.com

Moderna (MRNA) and Biogen (BIIB) - Are There Upsides Left in These Biotech Stocks?

Despite macroeconomic challenges, the biotech industry thrives on innovation, demand, adaptability, and technological advancements, demonstrating resilience. So, let’s analyze the upside potential of popular biotech stocks Biogen (BIIB) and Moderna (MRNA).

StockNews.com

Biogen (BIIB): Earnings Alert - Key Insights

Because of its strategic focus on research and therapy improvements for long-term growth, Biogen (BIIB) could come under heat for the mixed outcomes of its recent acquisitions. As stakeholders anticipate the forthcoming earnings release, let's seek insights into the company's future trajectory and implications for BIIB shares. Read on….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Buy, Hold, or Sell? Analyzing 3 Biotech Stocks Investors Are Watching

Amid the use of advanced technologies, personalized medicines, demand for quality treatments and therapies, and an aging population, the biotech industry appears to be on a steady path for expansion. Given this backdrop, let’s analyze the fundamentals of Biogen (BIIB), BioNTech (BNTX), and Kura (KURA) to determine which of these…

StockNews.com

GILD, BIIB, and KRTX: Biotech Buy, Hold, or Sell?

Rising healthcare needs, significant investments in R&D, robust drug pipeline, and use of advanced technology are some factors driving the biotech industry’s growth. Amid this favorable backdrop, let’s evaluate Gilead (GILD), Biogen (BIIB) and Karuna Therapeutics (KRTX) to determine the best investment action. Read more.

StockNews.com

Biogen (BIIB) Earnings Spotlight: Is the Biotech Stock a Buy or Sell?

Biotech major Biogen (BIIB) will report its third-quarter results on November 8. Its EPS and revenue are expected to decline year-over-year. However, the FDA approvals for new drugs received by the company this year will likely support its long-term growth. Let’s discuss the potential road ahead for the stock….

StockNews.com

3 Biotech Gainers to Consider

Robust demand, technological advancements, government and private investment, are fueling the biotech industry’s expansion and driving game-changing therapies and product development. With the industry anticipated to thrive, fundamentally strong biotech stocks Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and United Therapeutics (UTHR) look poised for substantial gains. Keep reading.

StockNews.com

3 Biotech Stocks Smart Money Is After

Biotech companies such as Biogen (BIIB), Cidara Therapeutics (CDTX), and Theratechnologies (THTX) with the interest of institutional investors could be worth investing in now. Continue reading….

StockNews.com

3 Biotech Stocks to Acquire in July

With the surge in new drug formulations, the growing prominence of personalized medicine, and favorable government initiatives, the biotech industry is set for significant growth this year and beyond. Thus, it could be wise to invest in fundamentally sound biotech stocks Biogen (BIIB), Alkermes (ALKS), and Theratechnologies (THTX) this month.…

StockNews.com

FDA Approves Biogen’s Alzheimer’s Drug That Slows Down Cognitive Decline

The FDA fully approved Biogen Inc. but there are other companies with treatments in the pipeline

Zenger

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Biotech Stocks With Some Major Value in Them

The worldwide need for healthcare and biotech products is experiencing a steady upsurge fueled by various factors, such as a heightened emphasis on personalized medicine. Therefore, it could be wise to explore three quality biotech stocks, Gilead Sciences (GILD), Biogen (BIIB), and Alkermes (ALKS), with significant value in them. Read…

StockNews.com

3 Biotech Stocks Every Investor Wants

Given inelastic demand, rapid breakthroughs, and government initiatives, the biotech industry looks well-positioned to thrive. So, quality biotech stocks Gilead Sciences (GILD), Biogen (BIIB), and Alkermes (ALKS) could be worth owning. Read on.

StockNews.com

3 Stocks Poised for Price Surges

Resurging concerns about the Fed’s hawkish stance to tame stubbornly high inflation and recessionary fears have weighed heavily on investors’ sentiments. Therefore, it could be wise to own fundamentally strong stocks Biogen (BIIB), Celestica (CLS), and Biglari Holdings (BH) that look poised to maintain their momentum. Read on….

StockNews.com

3 Biotech Stocks to Buy Now

The biotech industry is well-positioned to grow, given the inelastic demand, rapid advancements, and government initiatives. So, quality biotech stocks Biogen (BIIB), Alkermes (ALKS), and Vanda (VNDA) could be worth owning. Read on.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 of the Best Stocks in 1 of Wall Street's Worst-Rated Industry

After years of robust growth, the biotech industry has struggled since last year due to several headwinds, including regulatory concerns, inflation, and the Fed’s aggressive rate hikes, which have sucked out speculative capital. Despite currently being one of the poorly-rated industries, investors could consider buying top-biotech stocks Gilead (GILD), Vertex…

StockNews.com

4 Biotech Stocks You Don’t Want to Miss out on in 2023

The biotech industry is growing with considerable developments and government initiatives. Given the solid prospects of the industry, fundamentally sound biotech stocks Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Exelixis (EXEL), and Cidara Therapeutics (CDTX) could be excellent buys. Keep reading.

Tribune News Service

The VA will pay for some to get new Alzheimer’s drug

The U.S. Veterans Health Administration will pay for some beneficiaries to get a new Alzheimer’s disease drug from Eisai Co. and Biogen Inc., positive news for a treatment that Eisai expects to bring in billions of dollar in sales in the next few years.

StockNews.com

2 Top Biotech Stocks to Buy in March

The biotech industry is expected to witness solid growth amid impressive advancements and government initiatives. Moreover, the biotech sector tends to be more defensive than others during market downturns. So, fundamentally sound biotech stocks Amgen (AMGN) and Biogen (BIIB) might be ideal buys now. Keep reading.

StockNews.com

3 Biotech Stocks With Potential to Be Big Winners in 2023

The biotech industry is well-positioned to grow strongly, given the ever-rising demand for therapies and favorable government initiatives. Looking at the industry’s long-term prospects, fundamentally strong biotech stocks Amgen (AMGN), Biogen (BIIB), and Jazz Pharmaceuticals (JAZZ) could emerge as big winners this year. Keep reading….

StockNews.com

3 Biotech Stocks to Buy and Hold for the Next 20 Years

The biotech industry is well-positioned for long-term growth owing to strong demand and continued breakthroughs. Furthermore, favorable government funding should boost the industry’s growth. Hence, it could be wise to buy and hold fundamentally sound biotech stocks Amgen (AMGN), Biogen (BIIB), and Amicus Therapeutics (FOLD) for the next two decades.…

StockNews.com

3 No-Brainer Stocks to Buy Right Now Without Hesitation

Cooling inflation data and Fed’s recent 25 bps rate hike have contributed considerably to optimistic investor sentiment in the past few weeks. However, as opposed to an expected pause, the robust jobs report has raised prospects of further rate hikes in the coming months. Therefore, it could be wise to…

1 2 3 4

People

Dipanjan BanchurSince

722 stories

Steve Reitmeister

468 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

General Motors Company

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.